Pfizer's U.S. migraine portfolio includes NURTEC ODT and ZAVZPRET. NURTEC ODT is the first and only FDA-approved oral CGRP receptor antagonist for both acute and preventive migraine, aiming to set a new standard of care. ZAVZPRET, launched in July 2023, is the first intranasal CGRP monoclonal antibody for acute migraine treatment and is rapidly growing. Migraine affects 40 million people in the US, yet less than half are diagnosed, and fewer than half of those diagnosed are on prescription therapy. The Director of Access & Affordability Strategy and Execution will lead the strategic development and optimization of access and affordability initiatives to advance franchise business objectives, drive patient impact, and ensure gross-to-net performance.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Number of Employees
5,001-10,000 employees